Twelfth Annual BIO CEO & Investor Conference to Feature Clinical Thought Leaders, Industry Executives and Patient Groups

WASHINGTON, D.C. (Friday, January 08, 2010) - The Biotechnology Industry Organization (BIO) today announced the selection of therapeutic workshops to be presented at the Twelfth Annual BIO CEO & Investor Conference, taking place February 8-9 at the Waldorf=Astoria Hotel in New York City.  Experts chosen to speak on these panels represent leading clinical institutions, medical foundations, and public and private biotechnology companies. 


“This year’s BIO CEO & Investor Conference will provide a unique forum to showcase therapeutic areas with key catalysts – from new and dynamic therapies to cutting edge investment opportunities,” said Alan Eisenberg, executive vice president of Emerging Companies & Business Development at BIO.  “This conference provides industry executives, clinical thought leaders and investment professionals the opportunity to discuss therapeutic areas of need and expectations for the next decade’s market environment.”

This year, BIO is collaborating with Panel Intelligence (formerly MedPanel), a healthcare market research firm, to identify key opinion leaders based on knowledge and expertise in their respective fields and affiliations with prestigious academic institutions and medical foundations.

The BIO CEO & Investor Conference’s therapeutic workshops will focus on topics addressing the latest developments in therapies for a wide range of diseases. This year’s therapeutic workshop topics include:

Sarcoma: Connecting the Dots on New Therapies

Monday, February 8th, 9:00am-10:00am


·         John G. Curd, M.D.; President and Chief Medical Officer, Threshold Pharmaceuticals

·         Jonathan Lewis, M.D., Ph.D., Chief Executive Officer and Chief Medical Officer, ZIOPHARM Oncology

·         Robert G. Maki, M.D., Ph.D; Associate Member, Co-Leader, Adult Sarcoma Program, Memorial Sloan-Kettering Cancer Center

RNAi Based Technology: No Longer Single & Stranded

Monday, February 8, 12:30-1:35pm


·         Simos Simeonidis, PhD; Managing Director, Rodman & Renshaw, LLC

·         Noah D. Beerman, President and Chief Executive Officer, RXi Pharmaceuticals

·         J. Michael French; Chief Executive Officer, MDRNA

·         Alnylam Pharmaceuticals


Alzheimer’s Disease: A Panel to Remember

Tuesday, February 9th, 9:00am-10:00am

·         Tony Cruz, MD; Chief Executive Officer, Transition Therapeutics

·         David Hung, MD; President & Chief Executive Officer, Medivation

·         Carlos V. Paya, MD; PhD, President, Elan

·         Alzheimer’s Association

·         Steven Ferris, PhD; Friedman Professor and Director of Alzheimer’s Disease Center, Center of Excellence on Brain Agin, New York University Langone Medical Center


HCV: Liver Long & Prosper

Tuesday, February 9,12:00pm-1:00pm

·         M. Michelle Berrey, M.D., M.P.H.; Chief Medical Officer, Pharmasset

·         Robert S. Kauffman, M.D., Ph.D, Chief Medical Officer and Senior Vice President Clinical Development

·         Steve Worland, Ph.D.,; President & Chief Executive Officer, Anadys Pharmaceuticals

·         Douglas T. Dieterich, M.D.; Professor of Medicine, Director of Outpatient Hepatology in the Division of Liver Diseases and Director of CME in the Department of Medicine, Mount Sinai School of Medicine

Lupus: New Care for Too Much Flare

Tuesday, February 9th, 3:00pm-4:00pm

·         Mark Schoenebaum, MD; Managing Director & Senior Biotechnology Analyst, Deutsche Bank

·         Barry A. Labinger, Executive Vice President & Chief Commercial Officer, Human Genome Sciences

·         Sandra C. Raymond, President and Chief Executive Officer, Lupus Foundation of America

·         Richard Furie, M.D.; Chief of the Division of Rheumatology & Allergy-Clinical Immunology, North Shore-Long Island Jewish Health System


To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit  Registration is complimentary for qualified investors and credentialed members of the media.


The BIO CEO & Investor Conference is the largest independent investor conference focused solely on publicly-traded biotechnology companies.  The meeting attracts institutional investors, industry analysts, and senior biotechnology executives.  In addition, the BIO CEO & Investor Conference draws business development executives from leading global pharmaceutical and mature biotechnology companies.


BIO CEO & Investor Conference Bank Sponsors

BIO is pleased to acknowledge the leadership provided by the BIO CEO & Investor Conference bank sponsors, including Lead Bank Sponsor Wedbush PacGrow Life Sciences, Conference Co-Host Rodman & Renshaw, LLC and Supporting Bank Sponsor Lazard.


About Panel Intelligence

Panel Intelligence, formerly MedPanel, Inc., is proud to be working with BIO to provide leading industry experts on these therapeutic workshops. As a fully committed and capable research partner, Panel Intelligence works closely with BIO to identify objectives, recruit experts, elicit information, and synthesize results. Panel Intelligence's domain expertise, global network of experts, and proven online methods can provide due diligence on one particular company, investigate a particular space, evaluate an IPO, or identify market trends and consumer preferences.

Upcoming BIO Events

7th Annual BIO Asia Partnering Conference

January 25-26, 2010

Tokyo, Japan


12th Annual BIO CEO & Investor Conference

February 8-9, 2010

New York, NY

9th Annual Windhover & Windhover PSO
February 23-25, 2010
New York City, NY

BIO-Europe Spring
March 8-10, 2010
Barcelona, Spain

BIO Intellectual Property Counsels Spring Conference and Committee Meeting
April 19-21, 2010
New Orleans, LA 

Partnering for Global Health
May 3, 2010
Chicago, IL
McCormick Place Convention Center

BIO International Convention
May 3-6, 2010
Chicago, IL
McCormick Place Convention Center

2010 BIO Human Resources Conference
May 4-7, 2010
Chicago, IL


About BIO

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.